The Japan patent covers Rexahn’s preclinical compound RX-0047 and a method of inhibiting the expression of HIF-1 in human cells or tissues.
HIF-1, a human protein is involved in angiogenesis, cancer cell survival, radiation resistance and cancer metastasis.
RX-0047 has demonstrated the ability to inhibit the expression of HIF-1 and also to induce toxicity in several cancer cell lines.
Rexahn Pharma said the preclinical studies to date have demonstrated potent anti-proliferative, anti-tumor and anti-metastatic activities.
Rexahn Pharma president Rick Soni said obtaining this additional patent coverage for RX-0047 in the large pharmaceutical market of Japan is another step forward for the development of this compound, and helps strengthen our overall global intellectual property position.